ACTEMRA (tocilizumab)

ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) is the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody developed for the treatment of RA (rheumatoid arthritis) and is a novel approach to help tackle this debilitating disease. IL-6 has been identified as having a fundamental role in the inflammation process in RA.

For indication information see RoACTEMRA.

ACTEMRA is currently approved in Japan, US, the European Union (as RoACTEMRA), Switzerland, India, Moldova, Peru, Kuwait, Brazil and Liechtenstein and pending approvals in other countries around the world.